Le Lézard
Classified in: Health
Subject: MRR

Health Alert: Chagas Disease, Also Known as American Trypanosomiasis, Poses Life-Threatening Risk from Trypanosoma Cruzi Parasite: BCC Research LLC


Chagas disease, which is also known as American trypanosomiasis, occurs when you get infected with a small parasite called Trypanosoma cruzi. A doctor named Carlos RJ Chagas from Brazil discovered this parasite and how it causes illness in people way back in 1909.

BOSTON, April 16, 2024 /PRNewswire/ -- The new research gives a complete picture of the Chagas Disease: American trypanosomiasis market. It looks at trends in the CD market, including how common it is in different regions, and talks about what's happening in the market right now. The report also looks closely at the competition between different treatments. It focuses on treatments available across Latin America. Because many people with Chagas Disease don't have enough money to buy medicine, there isn't much demand for these products. That's why pharmaceutical companies aren't putting a lot of effort into creating new treatments for Chagas disease now.

BCC Research Logo

Key Facts to Know About Chagas Disease: A Quick Overview

ing it to someone, and testing and treating girls, women who can have babies, newborns, and brothers and sisters of infected moms who haven't had treatment before.

The Transmission of Chagas Disease in the American Market: Key Insights

In Latin America, Chagas disease mostly spreads from poop or pee of blood-sucking bugs called kissing bugs. These bugs hide in cracks in houses and come out at night to feed on blood. When they bite, they often do it on the face. If someone scratches the bite and gets the poop or pee in their body, they can get infected with the parasite.

T. cruzi can also be transmitted by:

Signs and symptoms

Chagas disease has two phases. In the first phase, which lasts about 2 months, a lot of parasites are in the blood, but most people don't have any symptoms or just feel a little unwell. Sometimes, people might see a spot on their skin or swelling around one eye. They could also have fever, headache, swollen glands, pale skin, muscle pain, trouble breathing, or pain in the belly or chest.

In the second phase, the parasites hide in the heart and stomach muscles. After one to three decades, about a third of patients have heart problems, and about one in ten have stomach issues. Over time, the infection can damage the nerves and heart muscles, causing heart problems, irregular heartbeats, heart failure, or sudden death.

Chagas Disease Treatment in the American Market

Chagas disease can be treated with medicines like benznidazole or nifurtimox to kill the parasite. These drugs work best if given early, especially during the first phase of the disease. Treatment can also help prevent the disease from getting worse. However, treatment can have side effects, and it's not recommended for pregnant women or people with certain health conditions. In some cases, additional treatment may be needed for heart, digestive, or nerve problems caused by the disease.

Control and Prevention

In different places, the World Health Organization WHO (World Health Organisation) suggests various ways to prevent and control Chagas disease:

Here are the top 5 key companies in the Chagas Disease (American trypanosomiasis) market along with brief descriptions:

  1. Bayer AG: A multinational pharmaceutical company known for its commitment to global health initiatives, including research and development of treatments for neglected tropical diseases like Chagas Disease.
  2. Sanofi S.A.: A leading pharmaceutical company with a focus on innovative treatments for various diseases, including neglected tropical diseases such as Chagas Disease.
  3. GlaxoSmithKline plc: A global healthcare company dedicated to developing vaccines and treatments for infectious diseases, including Chagas Disease.
  4. Novartis AG: A pharmaceutical company known for its research and development efforts in addressing unmet medical needs, including the development of therapies for neglected tropical diseases like Chagas Disease.
  5. Merck & Co., Inc.: A leading global healthcare company committed to developing innovative treatments and vaccines for a wide range of diseases, including Chagas Disease.

Directly Purchase a copy of the report with BCC Research.

For further information or to make a purchase, please get in touch with [email protected].

About BCC Research

BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts' goal is to help you make informed business decisions, free of noise and hype.

Contact Us

Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA

Email: [email protected],

Phone: +1 781-489-7301

For media inquiries, email [email protected] or visit our media page for access to our market research library.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo: https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg

 

SOURCE BCC Research LLC


These press releases may also interest you

at 19:15
In a recent round of grant awards, the STRONG STAR Consortium based at The University of Texas Health Science Center at San Antonio (UT Health San Antonio)...

at 18:50
Ontario's forest firefighters will soon have the same presumptive WSIB coverage that urban firefighters do. Like urban firefighters, forest firefighters are at a higher risk of cancer, heart disease and heart injuries, and post-traumatic stress...

at 18:49
A final FDA rule regulating laboratory-developed tests (LDTs) as medical devices does not address serious concerns raised by ARUP Laboratories and the clinical laboratory community, and the company's stance on the rule has not changed, CEO Andy...

at 18:45
Pfizer Inc. and Genmab A/S today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with...

at 18:45
Genmab A/S and Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or...

at 18:45
Pond Technologies Holdings Inc. (the "Corporation" or "Pond")  announces the filing of the audited consolidated financial statements of the Corporation for the twelve months ended December 31, 2023 and the related management's discussion and analysis...



News published on and distributed by: